4.1 Article

Minimum Alveolar Concentration-Awake of Sevoflurane is Decreased in Patients with Parkinson's Disease: An Up-and-Down Sequential Allocation Trial

期刊

CLINICAL INTERVENTIONS IN AGING
卷 16, 期 -, 页码 129-136

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/CIA.S291656

关键词

Parkinson's disease; sevoflurane; the minimum alveolar concentration-awake

资金

  1. Natural Science Foundation of Anhui Province of China [1908085MH251]
  2. Fundamental Research Funds for the Central Universities [WK9110000059]

向作者/读者索取更多资源

This study compared the minimum alveolar concentration-awake (MAC(awake)) of sevoflurane in Parkinson's disease (PD) patients with non-PD patients, finding that PD patients had a significantly lower MAC(awake) and clinicians should avoid overdosing sevoflurane in PD patients.
Background: An increasing number of patients with Parkinson's disease (PD) will have surgery under general anesthesia. A previous study demonstrated that propofol requirement for inducing unconsciousness in PD patients was lower than that in non-PD (NPD) patients. However, the requirement of inhaled anesthetics in PD patients has not been clarified. The aim of this study was to investigate the minimum alveolar concentration-awake (MAC(awake)) of sevoflurane in patients with PD compared to NPD patients. Patients and Methods: The current study is an up-and-down sequential allocation trial. The initial end-tidal concentration of sevoflurane (CETsevo) was estimated by the response of the previous patient to verbal command using the Dixon's up-and-down method. The first patient in each group received CETsevo at 1%, and the step size between patients was 0.2%. Results: Forty-one patients including 20 PD patients and 21 NPD patients were enrolled. Patients' characteristics and arterial blood gas parameters (except blood sodium) were comparable between two groups. The MAC(awake) of sevoflurane estimated by the Dixon's upand-down method in PD patients (0.47% +/- 0.08% [Mean +/- S.D.]) was significantly lower than that in NDP patients (0.64% +/- 0.10%) (P=0.003). The estimated difference in means was 0.17% (95% CI, 0.10-0.24%). Probit analysis showed that the MAC(awake )of sevoflurane in PD and NPD patients was 0.49% (95% CI, 0.42-0.57%) and 0.67% (95% CI, 0.59-0.76%), respectively. The relative median potency was 0.73 (95% CI, 0.38-0.94). Conclusion: Patients with PD exhibit a significantly lower MAC(awake) of sevoflurane compared with NPD patients. Clinicians should avoid an overdose of sevoflurane in patients with PD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据